Clinical trialNCT01584388CompletedPhase 1/PHASE2Interventional

Rituximab in IgG4-RD: A Phase 1-2 Trial

SponsorMassachusetts General HospitalEnrollment30Autoimmune PancreatitisPseudotumorRetroperitoneal FibrosisSialadenitis

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The primary objective of this study is to evaluate the safety and effectiveness of rituximab in IgG4-RD.

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Arezou Khosroshahi, MD
Massachusetts General Hospital (Rheumatology Unit)
Study DirectorKOL profile →
clinicaltrials.gov ↗
John H Stone, MD, MPH
Massachusetts General Hospital (Rheumatology Unit)
Study ChairKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

No facility list is in our current data snapshot for this study. The registry record on ClinicalTrials.gov ↗ carries any published locations. Why? →

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Rituximab →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 30 Apr 2012
Primary completion: 31 Jan 2014
Completion: 31 Jan 2015
Last update posted: 2 Jul 2017
Registered enrollment: 30
Registry id: NCT01584388

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.